Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) is pleased to announce it has received regulatory guidance concerning the appropriate preclinical steps necessary to initiate human clinical trials for its new drug, Nasodine™. After discussions with the FDA, the company is planning to conduct a 30-day repeat dose animal study prior to filing an investigational new drug (IND) application in 2007. Nasodine is a proprietary formulation designed to eliminate drug-resistant Staphylococcus aureus (Staph) in the nasal cavity. Symbollon believes the market opportunity for Nasodine could easily be in the hundreds of millions per year.
